All the news Showing 10 of 28 articles from: Pan-genotypic regimensGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources NICE nod for Gilead’s pan-genotypic hepatitis C therapy PharmaTimes / 21 February 2018 New three-drug HCV regimen shows nearly 100% response in 6, 8 weeks Healio Hepatology / 30 October 2017 European and US regulators approve AbbVie's new combo for all hepatitis C genotypes Liz Highleyman / 08 August 2017 The European Commission and the US Food and Drug Administration (FDA) last week approved AbbVie's new combination pill for people with hepatitis C virus (HCV) genotypes 1 to 6, to ... European Commission Grants Marketing Authorization for Gilead’s Vosevi® (Sofosbuvir/Velpatasvir/Voxilaprevir) for the Treatment of All Genotypes of Chronic Hepatitis C Gilead press release / 31 July 2017 European Commission Grants AbbVie's MAVIRET® (glecaprevir/pibrentasvir) Marketing Authorization for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6) AbbVie press release / 31 July 2017 Glecaprevir/pibrentasvir is effective for people with HIV/HCV co-infection Liz Highleyman / 26 July 2017 AbbVie's new pangenotypic regimen combining glecaprevir and pibrentasvir cured almost all HIV-positive people with hepatitis C co-infection in the EXPEDITION-2 study, according to a presentation on Monday at the 9th International AIDS Society ... US regulator approves Gilead's Vosevi combo pill for hepatitis C retreatment Liz Highleyman / 19 July 2017 On 18 July the US Food and Drug Administration (FDA) approved Gilead Sciences' Vosevi, a new once-daily combination pill containing sofosbuvir, velpatasvir, and voxilaprevir. Vosevi was approved as "salvage therapy" ... New pangenotypic hepatitis C drug combinations recommended for approval in the European Union Keith Alcorn / 26 June 2017 Two new pangenotypic direct-acting antiviral combinations have received positive opinions from the scientific committee of the European Medicines Agency (the CHMP) and should receive European Union marketing approval in next ... Glecaprevir/pibrentasvir effective for people with hepatitis C and severe kidney disease Liz Highleyman / 22 December 2016 A two-drug pangenotypic regimen combining AbbVie's glecaprevir and pibrentasvir demonstrated a high sustained response rate for people with chronic hepatitis C who have severe kidney impairment, according to results from the EXPEDITION-4 study ... 8-week triple DAA combo cures most people with genotype 1-6 hepatitis C Liz Highleyman / 21 November 2016 A three-drug regimen of sofosbuvir, velpatasvir and voxilaprevir taken for 8 weeks demonstrated an overall sustained virological response rate of 95% for previously untreated people with all hepatitis C virus (HCV) genotypes, while ... ← Prev123Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive